AR and posterior cortical atrophy: Low dose dox is unlikely to impact late stage PCa, yet the ability to enhance the differential effect between cARE- and sARE-driven genes may favor normal over tumorigenic functions of AR, and may thus be beneficial in watchful waiting or early stage disease.